An extension to the conditional marketing authorization of Adcetris (brentuximab vedotin) in the European Union has sent Takeda’s (TYO: 4502) share price up 2% in Tokyo today.
The European Medicines Agency has approved the anti-CD30 monoclonal antibody to treat certain cutaneous T-cell lymphoma (CTCL) patients in the second-line setting.
CTCL is a subtype of non-Hodgkin lymphoma that often mimics eczema or psoriasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze